Martín Ruiz-Ortiz

Dr. Martín Ruiz-Ortiz

orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2017 in EP Europace
Verified
Journal Article
Closed access
PDF file
Martín Ruiz-OrtizMartín Ruiz-Ortiz
Martín Ruiz-Ortiz
JMJavier Muñiz
Javier Muñiz
PMPaula Raña Míguez
Paula Raña Míguez
IRInmaculada Roldán
Inmaculada Roldán
FMFrancisco Marin
Francisco Marin
MAManuel Anguita
Manuel Anguita
To describe the prevalence and associated factors of inappropriate doses of direct oral anticoagulants (DOAC) in a national registry of patients of real clinical practice. Five hundred and thirty outpatients with atrial fibrillation treated with DOAC were included in a prospective, national, multicentre study. The appropriateness of the doses of DOAC was defined according to the recommendations of the European Heart Rhythm Association. Mean age was 73 ± 9 years, with a 46% of women. Two hundred and sixty-seven patients were prescribed dabigatran, 190 rivaroxaban, and 73 apixaban. A total of 172 patients (32%) did not receive the appropriate dose: 93 patients received a lower dose (18%) and 79 patients a higher dose (15%). In the comparisons among the subgroups of inappropriately low, appropriate, and inappropriately high dose, we observed significant trends to older age (69 ± 8 years vs. 73 ± 10 years vs. 77 ± 6 years), more frequent female sex (37% vs. 46% vs. 59%), antiplatelet drugs (5% vs. 8% vs. 25%), rivaroxaban (14% vs. 38% vs. 53%), and apixaban use (5% vs. 15% vs. 19%), higher CHAD2DS2-VASc (3.00 ± 1.38 vs. 3.58 ± 1.67 vs. 4.59 ± 1.44) and HAS-BLED scores (1.83 ± 0.87 vs. 1.92 ± 1.07 vs. 2.47 ± 1.13), lower body mass index (30 ± 6 kg/m2 vs. 29 ± 4 kg/m2 vs. 28 ± 4 kg/m2) and glomerular filtration rate (74 ± 27 mL/min vs. 70 ± 22 mL/min vs. 63 ± 16 mL/min), and lower frequency of dabigatran use (81% vs. 47% vs. 28%) (all comparisons P ≤ 0.01). In this real-life study, 32% of patients received an inappropriate dose of DOAC. Several clinical factors can identify patients at risk of this situation.

1 January 2015 in Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
VBVicente Bertomeu
Vicente Bertomeu
ÁCÁngel Cequier
Ángel Cequier
FMFrancisco Marin
Francisco Marin
MAManuel Anguita
Manuel Anguita
Martín Ruiz-OrtizMartín Ruiz-Ortiz
Martín Ruiz-Ortiz
The SAMe-TT2R2 score has been proposed to identify patients with non valvular atrial fibrillation (AF) who maintain a high average time in therapeutic range (TTR) on vitamin K antagonists treatment (VKA). This score has been validated in several studies, either monocentric or including very selected populations in a specialised setting. Our objective was to validate this score in a nationwide cohort of AF patients. From November 2013 to March 2014 we included in this study the first 10 patients with AF on VKA consecutively seen in 120 outpatient cardiology clinics in Spain. The SAMe-TT2R2 score was calculated for each patient and TTR in the preceding six months was estimated by Rosendaal method. A total of 1,056 patients were recruited (mean age 73.6 ± 9.8 years, 42 % female). Mean value of TTR was 63.8 ± 25.9 % (median 66.8 %, interquartile range 45.6 %-85.4 %). We found a progressive decline in mean TTR from a score of 0 (67.5 % ± 24.6 %) to4 (52.7 ± 28.7 %, p< 0.01). The score was able to discriminate which patients had a good anticoagulation control (TTR65 %) with a C-statistic of 0.57 (95 %CI 0.53–0.60, p< 0.0005). A SAMe-TT2R2 score of 0–1 was associated with a good anticoagulation control with a sensitivity, specificity, positive and negative predictive values of 64 %, 48 %, 58 % and 54 %, respectively; and the odds ratio of having a TTR< 65 % if the score was2 was 1.64 (95 % confidence interval 1.33–1.95, p< 0.001). In conclusion, in this nationwide population with AF on VKA, the SAMe-TT2R2 score had a significant, although moderate, ability to identify patients with a good anticoagulation control.

2 June 2021 in European Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
JBJuan Luis Bonilla-Palomas
Juan Luis Bonilla-Palomas
MAManuel P. Anguita‐Sánchez
Manuel P. Anguita‐Sánchez
FEFrancisco J. Elola‐Somoza
Francisco J. Elola‐Somoza
JBJosé L. Bernal‐Sobrino
José L. Bernal‐Sobrino
CFCristina Fernández‐Pérez
Cristina Fernández‐Pérez
FMFrancisco Marín‐Ortuño
Francisco Marín‐Ortuño

10 May 2014 in Echocardiography
Verified
Journal Article
Closed access
PDF file
Martín Ruiz-OrtizMartín Ruiz-Ortiz
Martín Ruiz-Ortiz
MPMaría Luisa Peña
María Luisa Peña
DRDolores Mesa Rubio
Dolores Mesa Rubio
MDMónica Delgado
Mónica Delgado
ERElías Romo
Elías Romo
JLJosé Suárez de Lezo
José Suárez de Lezo

15 March 2022 in Cancers
Verified
Journal Article
Open access
PDF file
RGRafael Gonzalez-Manzanares
Rafael Gonzalez-Manzanares
JDJUAN CARLOS CASTILLO DOMINGUEZ
JUAN CARLOS CASTILLO DOMINGUEZ
JMJose R. Molina
Jose R. Molina
Martín Ruiz-OrtizMartín Ruiz-Ortiz
Martín Ruiz-Ortiz
DRDolores Mesa Rubio
Dolores Mesa Rubio
MPManuel Pan
Manuel Pan
There is limited evidence that supports the use of the global longitudinal strain (GLS) in long-term cardiac monitoring of childhood acute lymphoblastic leukemia survivors (CLSs). Our aim was to assess the utility of automated GLS to detect left ventricular systolic dysfunction (LVSD) in long-term CLSs. Asymptomatic and subclinical LVSD were defined as LVEF < 50% and GLS < 18.5%, respectively. Echocardiographic measurements and biomarkers were compared with a control group. Inverse probability weighting was used to reduce confounding. Regression models were used to identify factors associated with LVEF and GLS in the survivors. Ninety survivors with a median follow-up of 18 (11–26) years were included. The prevalence of LVSD was higher using GLS than with LVEF (26.6% vs. 12.2%). The measurements were both reduced as compared with the controls (p < 0.001). There were no differences in diastolic parameters and NT-ProBNP. Survivors were more likely to have Hs-cTnI levels above the detection limit (40% vs. 17.2%, p = 0.006). The dose of anthracycline was associated with LVEF but not with GLS in the survivors. Biomarkers were not associated with GLS or LVEF. In conclusion, LVSD detection using automated GLS was higher than with LVEF in long-term CLSs. Its incorporation into clinical routine practice may improve the surveillance of these patients.

1 December 1996 in American Heart Journal
Verified
Journal Article
Closed access
MPManuel Pan
Manuel Pan
JLJosé Suárez de Lezo
José Suárez de Lezo
FVFrancisco Velasco
Francisco Velasco
MRMiguel Romero
Miguel Romero
AMAlfonso Medina
Alfonso Medina
ATAntonio Torres
Antonio Torres